Applying multiomics to novel target discovery in immuno-oncology
August 08, 2023
Eran Ophir and Yaron Turpaz
In this episode, Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks with Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about the advantages of using multiomic and computational approaches for the discovery of novel targets and mechanisms of action (MoA) of novel drug candidates in immuno-oncology.
Can you both tell me a bit about your current roles and the work you do?
Can you outline how you are applying multiomics to novel target discovery in the I-O space?
What advantages do multiomics approaches offer, and what for you is the cutting edge in this space?
Can you tell me about Compugen’s computational approach to developing an I–O pipeline?
What have been your biggest milestones to date, and what’s next?
The development of diagnostic/prognostic biomarkers remains a key challenge for the I–O space–how can computational approaches help these efforts?
What would be top of your wish list for new tools/innovations in this space?